ResearchPod Summary
Methamphetamine (MA) use disorder is associated with significant neuroinflammation, which is hypothesized to contribute to neurodegeneration and impaired treatment outcomes. Ibudilast (IBUD), a non-selective phosphodiesterase inhibitor with anti-inflammatory properties, has shown promise in preclinical models by modulating glial cell activation and reducing MA-related behaviors. This trial sought to determine whether IBUD could improve clinical outcomes—specifically, sustained abstinence—in treatment-seeking adults with MA use disorder.
The research team conducted a 12-week, randomized, double-blind, placebo-controlled Phase II trial with 125 participants. Volunteers were split into an IBUD group (50 mg twice daily) and a placebo group. Both groups received medication management counseling, a low-intensity behavioral platform, throughout the study. The primary outcome was end-of-treatment methamphetamine abstinence, measured by urine drug screens during the final two weeks of the study.
The study did not find evidence that ibudilast outperforms placebo. Only 14% of the IBUD group achieved the primary outcome of end-of-treatment abstinence, compared to 16% in the placebo group—a difference that was not statistically significant. Secondary outcomes, including retention in the program and the number of MA-negative urine screens, also showed no significant benefit for the medication group. Further, serum drug levels confirmed that the lack of effect was not simply due to poor medication adherence.
This trial adds to the growing list of pharmacological interventions that have failed to show efficacy in treating methamphetamine use disorder. While the hypothesis that targeting neuroinflammation could mitigate the neurobiological damage caused by chronic MA use remains theoretically compelling, this study suggests that IBUD at the studied dose and duration does not resolve the behavioral challenges of active addiction. The authors suggest that future research must look beyond simple pharmacological targets and potentially refine study designs to address the severe, complex nature of methamphetamine dependence.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.